Pitt Street Research Interviews CEO Steven Lydeamore
Pitt Street Research Interviews CEO Steven Lydeamore
Brisbane, April 16, 2019 AEST (ABN Newswire) - While in Sydney earlier this month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Stuart Roberts at Pitt Street Research, one of Australia's most experienced providers of equity research for ASX-listed small and mid cap companies.

Stuart spoke with Steve about the path to market for the Company's new gastrointestinal reprogramming dietary supplement product, called GaRP.

Based on bromelain, GaRP has shown promise as a potential treatment for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Anatara believes there is significant upside for this product given the lack of strong treatment alternatives and the high prevalence of IBS and IBD.

To view the interview, please visit:

To view the latest Corporate Fact Sheet for further information on Anatara Lifesciences, please visit:

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.



General inquiries
Steven Lydeamore
Anatara Lifesciences
T: +61-438-027-172
E: slydeamore@anatara.com

Media inquiries:
Jane Lowe
Managing Director
IR Department
T: +61-411-117-774
E: jane.lowe@irdepartment.com.au

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 12) (Last 30 Days: 49) (Since Published: 2985)